HRP20200818T1 - Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitijela - Google Patents
Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitijela Download PDFInfo
- Publication number
- HRP20200818T1 HRP20200818T1 HRP20200818TT HRP20200818T HRP20200818T1 HR P20200818 T1 HRP20200818 T1 HR P20200818T1 HR P20200818T T HRP20200818T T HR P20200818TT HR P20200818 T HRP20200818 T HR P20200818T HR P20200818 T1 HRP20200818 T1 HR P20200818T1
- Authority
- HR
- Croatia
- Prior art keywords
- agent
- inhibitor
- group
- antagonist
- fibrosis
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title claims 4
- 230000004761 fibrosis Effects 0.000 title claims 4
- 230000000116 mitigating effect Effects 0.000 title 1
- 230000000451 tissue damage Effects 0.000 title 1
- 231100000827 tissue damage Toxicity 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 4
- 102000003945 NF-kappa B Human genes 0.000 claims 4
- 108010057466 NF-kappa B Proteins 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000028709 inflammatory response Effects 0.000 claims 4
- 239000007952 growth promoter Substances 0.000 claims 3
- 230000037257 muscle growth Effects 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 102000016970 Follistatin Human genes 0.000 claims 2
- 108010014612 Follistatin Proteins 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 102000008121 Latent TGF-beta Binding Proteins Human genes 0.000 claims 2
- 108010049807 Latent TGF-beta Binding Proteins Proteins 0.000 claims 2
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims 2
- 208000029549 Muscle injury Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 108091008611 Protein Kinase B Proteins 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000037892 acute myocardial injury Diseases 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102100035784 Decorin Human genes 0.000 claims 1
- 108090000738 Decorin Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims 1
- 108091005735 TGF-beta receptors Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims 1
- 229960001117 clenbuterol Drugs 0.000 claims 1
- 229960003624 creatine Drugs 0.000 claims 1
- 239000006046 creatine Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Agens koji inhibira proteolizu latentnog TGFβ vezujućeg proteina 4 (LTBP4) za upotrebu u liječenju pacijenta koji pati od bolesti koja je izabrana iz grupe koja se sastoji od Duchenne mišićne distrofije, udno pojasne mišićne distrofije, Beckerove mišićne distrofije, miopatije, cistične fibroze, plućne fibroze, kardiomiopatije, akutne ozljede pluće, akutne ozljede mišića, i akutne miokardijalne ozljede, gdje je agens izolirano antitijelo koje se specifično veže za peptid koji se sastoji od sekvence koja je predstavljena u SEQ ID NO: 6.
2. Agens za upotrebu prema zahtjevu 1 gdje upotreba dalje obuhvaća davanje efikasne količine drugog agensa koji je izabran iz grupe koja se sastoji od inhibitora upalnog odgovora, promotora mišićnog rasta, i inhibitora fibroze, gdje inhibitor upalnog odgovora je agonist beta2-adrenergičkog receptora, inhibitor nuklearnog faktora kapa-B (NF-κB), antagonist faktora nekroze tumora alfa (TNF-α), ili ciklosporin.
3. Izolirano antitijelo koje se specifično veže za peptid koji se sastoji od sekvence koja je predstavljena u SEQ ID NO: 6.
4. Farmaceutska formulacija koja sadrži efikasnu količinu antitijela prema zahtjevu 3 i farmaceutski prihvatljivog nosača ili razrjeđivača.
5. Formulacija prema zahtjevu 4 koja sadrži efikasnu količinu antitijela prema zahtjevu 3 i dalje sadrži efikasnu količinu drugog agensa, gdje je drugi agens izabran iz grupe koja se sastoji od inhibitora upalnog odgovora, promotora mišićnog rasta, kemoterapeutskog agensa i inhibitora fibroze, gdje inhibitor upalnog odgovora je agonist beta2-adrenergičkog receptora, inhibitor nuklearnog faktora kapa-B (NF-κB), antagonist faktora nekroze tumora alfa (TNF-α), ili ciklosporin.
6. Formulacija prema zahtjevu 5 gdje je drugi agens promotor mišićnog rasta izabran iz grupe koja se sastoji od inzulin-sličnog faktora rasta-1 (IGF-1), Akt/proteinske kinaze B, klenbuterola, kreatina, dekorina, steroida i testosterona.
7. Formulacija prema zahtjevu 5 gdje je drugi agens izabran iz grupe koja se sastoji od antitijela specifičnog za faktor-8 rasta i diferencijacije (GDF-8), antitijela za GDF-8 receptor, topljivog GDF-8 receptora, GDF-8 propeptida, follistatina, i proteina koji sadrži follistatin domenu.
8. Formulacija prema zahtjevu 5 gdje je drugi agens inhibitor fibroze izabran iz grupe koja se sastoji od pirfenidona, inhibitora angiotenzin-konvertirajućeg enzima (ACE), antagonista TGFβ, antagonista VEGF, antagonista receptora za VEGF, antagonista za TGFβ receptor, blokatora receptora za angiotenzin, i antagonista aldosterona.
9. Formulacija prema zahtjevu 4 za upotrebu u liječenju pacijenta koji pati od bolesti koja je izabrana iz grupe koja se sastoji od Duchenne mišićne distrofije, udno pojasne mišićne distrofije, Beckerove mišićne distrofije, miopatije, cistične fibroze, plućne fibroze, kardiomiopatije, akutne ozljede pluća, akutne ozljede mišića, i akutne miokardijalne ozljede.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261678564P | 2012-08-01 | 2012-08-01 | |
| PCT/US2013/053255 WO2014039189A1 (en) | 2012-08-01 | 2013-08-01 | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
| EP13835243.0A EP2880053B8 (en) | 2012-08-01 | 2013-08-01 | Mitigating tissue damage and fibrosis via anti-ltbp4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200818T1 true HRP20200818T1 (hr) | 2020-08-07 |
Family
ID=50025687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200818TT HRP20200818T1 (hr) | 2012-08-01 | 2020-05-20 | Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitijela |
Country Status (15)
| Country | Link |
|---|---|
| US (9) | US9873739B2 (hr) |
| EP (2) | EP2880053B8 (hr) |
| AU (5) | AU2013313282B2 (hr) |
| CA (1) | CA2880649C (hr) |
| CY (1) | CY1123029T1 (hr) |
| DK (1) | DK2880053T3 (hr) |
| ES (1) | ES2791778T3 (hr) |
| HK (1) | HK1211307A1 (hr) |
| HR (1) | HRP20200818T1 (hr) |
| HU (1) | HUE049217T2 (hr) |
| PL (1) | PL2880053T3 (hr) |
| PT (1) | PT2880053T (hr) |
| RS (1) | RS60318B1 (hr) |
| SI (1) | SI2880053T1 (hr) |
| WO (1) | WO2014039189A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY186389A (en) | 2014-05-13 | 2021-07-22 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
| WO2016054155A1 (en) * | 2014-09-30 | 2016-04-07 | Primegen Biotech, Llc. | Treatment of fibrosis using deep tissue heating and stem cell therapy |
| US10225675B2 (en) | 2015-02-17 | 2019-03-05 | Electronics And Telecommunications Research Institute | Multichannel signal processing method, and multichannel signal processing apparatus for performing the method |
| WO2016200543A2 (en) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-inluenza antibodies and methods of use thereof |
| HRP20240257T1 (hr) | 2017-02-28 | 2024-05-24 | The Trustees Of The University Of Pennsylvania | Adeno-povezani virusni (aav) clade f vektor i njegova uporaba |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| SG11201907611WA (en) | 2017-02-28 | 2019-09-27 | Univ Pennsylvania | Influenza vaccines based on aav vectors |
| EP3897689A1 (en) | 2018-12-21 | 2021-10-27 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5372807A (en) | 1990-05-14 | 1994-12-13 | University Of Medicine And Dentistry Of New Jersey | Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| MXPA01007366A (es) | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
| JP2002541253A (ja) | 1999-04-09 | 2002-12-03 | スミスクライン・ビーチャム・コーポレイション | トリアリールイミダゾール |
| EA005248B1 (ru) | 1999-07-20 | 2004-12-30 | Фармекса А/С | Способ отрицательной регуляции активности gdf-8 |
| WO2001053350A1 (en) | 2000-01-18 | 2001-07-26 | Agresearch Limited | Myostatin and mimetics thereof |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| AU2002225730A1 (en) | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
| GB0102668D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| CA2476887A1 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
| JP2006507356A (ja) | 2002-09-16 | 2006-03-02 | ワイエス | ミオスタチンのメタロプロテアーゼ活性化およびミオスタチン活性の調節方法 |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US7511012B2 (en) | 2002-12-20 | 2009-03-31 | Amgen Inc. | Myostatin binding agents |
| WO2004083241A2 (en) | 2003-03-19 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Btc-interacting proteins and use thereof |
| CA2558478A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| WO2005094446A2 (en) | 2004-03-23 | 2005-10-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| EP2314617B1 (en) | 2004-07-23 | 2015-06-24 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
| WO2006025988A1 (en) | 2004-07-29 | 2006-03-09 | Schering-Plough Ltd. | Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals |
| CA2605723A1 (en) | 2005-04-25 | 2006-11-02 | Pfizer Inc. | Antibodies to myostatin |
| AU2009270793A1 (en) * | 2008-07-18 | 2010-01-21 | Oragenics, Inc. | Compositions for the detection and treatment of colorectal cancer |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| FR2943249B1 (fr) | 2009-03-18 | 2011-08-12 | Genethon | Utilisation de la decorine pour augmenter la masse musculaire |
| WO2010108215A1 (en) | 2009-03-23 | 2010-09-30 | The Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for modulating an immune response |
| JP5931720B2 (ja) | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療 |
| WO2012006181A2 (en) * | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
-
2013
- 2013-08-01 PT PT138352430T patent/PT2880053T/pt unknown
- 2013-08-01 PL PL13835243T patent/PL2880053T3/pl unknown
- 2013-08-01 DK DK13835243.0T patent/DK2880053T3/da active
- 2013-08-01 US US13/957,100 patent/US9873739B2/en active Active
- 2013-08-01 AU AU2013313282A patent/AU2013313282B2/en active Active
- 2013-08-01 SI SI201331718T patent/SI2880053T1/sl unknown
- 2013-08-01 EP EP13835243.0A patent/EP2880053B8/en active Active
- 2013-08-01 EP EP20152849.4A patent/EP3711771A1/en active Pending
- 2013-08-01 HU HUE13835243A patent/HUE049217T2/hu unknown
- 2013-08-01 ES ES13835243T patent/ES2791778T3/es active Active
- 2013-08-01 CA CA2880649A patent/CA2880649C/en active Active
- 2013-08-01 RS RS20200604A patent/RS60318B1/sr unknown
- 2013-08-01 WO PCT/US2013/053255 patent/WO2014039189A1/en active Application Filing
-
2015
- 2015-12-09 HK HK15112163.9A patent/HK1211307A1/xx unknown
-
2017
- 2017-12-28 US US15/857,122 patent/US20180134785A1/en not_active Abandoned
-
2018
- 2018-01-04 AU AU2018200078A patent/AU2018200078A1/en not_active Abandoned
- 2018-09-05 US US16/122,333 patent/US20190002557A1/en not_active Abandoned
-
2019
- 2019-04-23 US US16/392,108 patent/US20190256589A1/en not_active Abandoned
- 2019-08-28 AU AU2019222850A patent/AU2019222850A1/en not_active Abandoned
- 2019-12-16 US US16/716,382 patent/US20200123247A1/en not_active Abandoned
-
2020
- 2020-05-20 HR HRP20200818TT patent/HRP20200818T1/hr unknown
- 2020-05-25 CY CY20201100496T patent/CY1123029T1/el unknown
- 2020-08-14 US US16/994,225 patent/US20200385457A1/en not_active Abandoned
-
2021
- 2021-02-08 AU AU2021200783A patent/AU2021200783B2/en active Active
- 2021-03-31 US US17/219,845 patent/US20210238274A1/en not_active Abandoned
- 2021-11-29 US US17/536,768 patent/US20220089717A1/en not_active Abandoned
-
2022
- 2022-07-07 US US17/811,233 patent/US20230235044A1/en not_active Abandoned
- 2022-11-15 AU AU2022271391A patent/AU2022271391A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200818T1 (hr) | Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitijela | |
| US11612639B2 (en) | Methods and compositions for rejuvenating skeletal muscle stem cells | |
| Zou et al. | Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4 | |
| J Fairclough et al. | Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy | |
| ES2535000T3 (es) | Composiciones para el tratamiento de cáncer | |
| CN103314006B (zh) | 新型血管紧张素2型（at2）受体激动剂及其应用 | |
| WO2010132580A2 (en) | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | |
| Bhattacharyya et al. | Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action | |
| Bhutani et al. | Emerging therapies for the treatment of osteoporosis | |
| Moody et al. | Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation | |
| EP3870203A1 (en) | Therapeutic combinations of tdfrps and additional agents and methods of use | |
| MX347229B (es) | Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso. | |
| Gendron et al. | FTY720 promotes pulmonary fibrosis when administered during the remodelling phase following a bleomycin-induced lung injury | |
| AU2021221579A1 (en) | Inhibitors of NF kappa-B activity for treatment of diseases and disorders | |
| Rachner et al. | Novel therapies in benign and malignant bone diseases | |
| JP2014515747A5 (hr) | ||
| Dong et al. | NRF2 is a critical regulator and therapeutic target of metal implant particle-incurred bone damage | |
| Li et al. | Secreted phosphoprotein 24 kD (Spp24) inhibits growth of human pancreatic cancer cells caused by BMP-2 | |
| Salido-Medina et al. | BMP7-based peptide agonists of BMPR1A protect the left ventricle against pathological remodeling induced by pressure overload | |
| JP2013510832A5 (hr) | ||
| Ochodnicky et al. | Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat | |
| HRP20211627T1 (hr) | Farmaceutski pripravak koji se sastoji od agonista receptora čimbenika rasta i proteina inhibitora adhezije za pretvaranje neoplastične stanice u neneoplastičnu stanicu i njegova upotreba | |
| Elesgaray et al. | Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide | |
| Shen et al. | Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy | |
| Kawai et al. | Prevention of skeletal muscle atrophy in vitro using anti-ubiquitination oligopeptide carried by atelocollagen |